Semaglutide and GLP-1 analogues as weight-loss agents

Lancet. 2018 Aug 25;392(10148):615-616. doi: 10.1016/S0140-6736(18)31826-9. Epub 2018 Aug 16.

Authors

Aaron Y Kluger¹, Peter A McCullough²

Affiliations

¹ Baylor Heart and Vascular Institute, Dallas, TX 75226, USA; Baylor Scott and White Research Institute, Dallas, TX, USA.
² Baylor Heart and Vascular Institute, Dallas, TX 75226, USA; Baylor Scott and White Research Institute, Dallas, TX, USA; Baylor University Medical Center, Dallas, TX, USA; Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, USA. Electronic address: peteramccullough@gmail.com.

PMID: 30122306
DOI: 10.1016/S0140-6736(18)31826-9

No abstract available

Publication types

Comment

MeSH terms

Anti-Obesity Agents*
Diabetes Mellitus, Type 2
Glucagon-Like Peptide 1
Glucagon-Like Peptides
Hypoglycemic Agents*

Substances

Anti-Obesity Agents
Hypoglycemic Agents
semaglutide
Glucagon-Like Peptides
Glucagon-Like Peptide 1